Sign in Subscribe
Pharmaceutical industry

COVID-19 Vaccines: Global Market Trajectory & Analytics

Strategic Insights

— 2 min read

As the world grapples with the ongoing pandemic, a new report by Global Industry Analysts Inc. provides a comprehensive analysis of the COVID-19 vaccines market, highlighting trends, opportunities, and challenges. The report, "COVID-19 Vaccines - Global Market Trajectory & Analytics," offers a fresh perspective on the post-COVID-19 marketplace, presenting data and insights on the rapidly evolving vaccine landscape.

Key Takeaways:

  • Approximately 53% of the world's population is expected to be fully vaccinated by the end of 2021, increasing to 81% by 2022, as a result of rapid vaccination programs launched globally.
  • The relaxation of measures designed to limit the spread of COVID-19, such as mask mandates and capacity limits, has strengthened consumer confidence and allowed economic activity to return to normalcy.
  • However, the emergence of new variants, such as the Delta variant, poses a threat of potential future waves, with these variants being more deadly, easily transmissible, and impacting the effectiveness of vaccines.
  • Messenger RNA (mRNA)-based COVID-19 vaccines from Moderna and Pfizer stand out as frontrunners, offering protection against newer variants, and demonstrating efficacy in early animal testing against viruses such as influenza, Zika, and rabies.
  • The leading vaccine makers, Pfizer-BioNTech, Moderna, and AstraZeneca, have announced plans to pursue booster shots to address the emerging threat of new virus variants, with Germany, the US, and Israel considering booster shots to increase protection against COVID-19.
  • A number of countries, including Australia, the UK, and India, have authorized the use of Pfizer's COVID-19 vaccine for vulnerable children aged between 12 and 15 years old, as cases of the highly contagious Delta variant rise sharply.
  • Despite the current authorization, clinical trials are under way to evaluate the efficacy of mRNA vaccines in younger children, with a focus on promoting rapid economic recovery and pandemic control.

Statistics:

  • Approximately 53% of the world's population is expected to be fully vaccinated by the end of 2021.
  • 81% of the world's population is expected to be fully vaccinated by 2022.
  • The Delta variant accounts for the vast majority of new infections.
  • mRNA-based COVID-19 vaccines from Pfizer/BioNTech and Moderna will be offered as booster shots, regardless of the vaccine administered previously.
  • The booster shot is essential to keep the immune system to the optimum level.
  • Studies suggest that a third dose can boost antibodies in the blood of some immunocompromised patients.
  • Israel is administering third doses of the Pfizer vaccine to immunocompromised people, including those who have had heart, lung, kidney, or liver transplants and cancer patients receiving chemotherapy.
  • Vaccinating young children and teenagers is crucial to significantly slow the spread of COVID-19 and achieve herd immunity.

Sources:

  • Global Industry Analysts Inc.
  • "COVID-19 Vaccines - Global Market Trajectory & Analytics" report
  • PRNewswire press release, September 2, 2021
  • Moderna press release, August 2021
  • Pfizer press release, August 2021
  • AstraZeneca press release, August 2021
  • StrategyR MarketGlass Platform
  • Global Industry Analysts, Inc. website

Read more